[go: up one dir, main page]

KR910011250A - 향정신성 약물의 안정화 용액 - Google Patents

향정신성 약물의 안정화 용액 Download PDF

Info

Publication number
KR910011250A
KR910011250A KR1019900019904A KR900019904A KR910011250A KR 910011250 A KR910011250 A KR 910011250A KR 1019900019904 A KR1019900019904 A KR 1019900019904A KR 900019904 A KR900019904 A KR 900019904A KR 910011250 A KR910011250 A KR 910011250A
Authority
KR
South Korea
Prior art keywords
methionine
mixture
mixtures
aqueous solution
stabilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900019904A
Other languages
English (en)
Other versions
KR0185377B1 (ko
Inventor
요하네스 마리아 반 덴 오이텔라 페트루스
마티나 프란시스 카 멘팅크 마리아
Original Assignee
에프.쥐.엠.헤르만스 피.씨.샬크비크
악조 엔. 브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.쥐.엠.헤르만스 피.씨.샬크비크, 악조 엔. 브이 filed Critical 에프.쥐.엠.헤르만스 피.씨.샬크비크
Publication of KR910011250A publication Critical patent/KR910011250A/ko
Application granted granted Critical
Publication of KR0185377B1 publication Critical patent/KR0185377B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

향정신성 약물의 안정화 용액
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. L-메티오닌, D-메티오닌, DL-메티오닌 및 그것의 혼합물중에서 안정화제를 선택하며, 상기 안정화제를 물과 혼합하고, 물중의 상기 선별된 안정화제 농도에서 안정화 될 수 있는 치료에 유용한 농도의 트리시클릭 또는 테트라 시클릭 질소 헤테로 시클릭와, 함께 더 혼합하는 것을 포함한 안정한 수용성 제제.
  2. 제1항에 있어서, 트리시클릭 또는 테트라시클릭 질소 헤테로시클릭이 혼합물 1ml당 약1내지 약5mg의 양으로 존재하는 마이안세린인 안정한 수용성제제.
  3. 제1항에 있어서, 트리시클릭 또는 테트라시클릭 질소 헤테로시클릭이 혼합물 1ml당 약1내지 약5mg의 양으로 존재하는 미트아제핀(mirtazapine) 또는 그것의 약제학적 허용 산부가염 또는 약제학적 허용 4급 암모늄염인 안정한 수용성제제.
  4. 제1항에 있어서, 상기의 안정화제는 메티오닌의 이성질체 또는 라세믹 혼합물이며, 상기의 트리시클릭 또는 테트라시클릭 질소 헤테로시클릭이 미트 아제핀, 마이안세린, 아미트립트린, 세티프틸린 및 그것의 혼합물에서 선택된 안정한 수용성 제제.
  5. 제4항에 있어서, 상기의 트리시클릭 또는 테트라시클릭 질소 헤테로시클릭이 미트아제핀인 안정한 수용성제제.
  6. 수용액중에서 헤티로시클릭을 안정화시키기 위하여 충분한 양의 L-메티오닌, D-메티오닌, DL-메티오닌 또는 그것의 혼합물과 함께 용해시켜서 혼합하는 것을 포함한 미트아제핀, 마이안세린, 세티프틸린, 아미트립트란 및 그것의 혼합물중에서 선택되 헤테로시클릭의 수용성 혼합물을 안정화시키는 방법.
  7. 미트아제핀, 마이안세린, 세티프틸린, 아미트립트린 및 그것의 혼합물에서 선택한 헤테로시클릭을, 혼합물중에서, 수용액 1ml당 약1 내지 5mg의 양으로 포함하며 수용액중의 상기 헤테로시클릭을 안정화시키기 위한 충분한 양의 L-메티오닌, D-메티오닌, DL-메티오닌 또는 그것의 혼합물을 포함한 안정화된 수용액.
  8. 제7항에 있어서, 헤테로시클릭이 미트아제핀이며 이것을 안정화시키기 위한 화합물은 L-메티오닌,D-메티오닌,DL-메티오닌, 또는 그것의 혼합물로서 수용액 1ml당 약0.05 내지 약5mg의 양으로 존재하는 안정화된 수용액.
  9. 제8항에 있어서, 미트아제핀을 안정화시키기 위한 화합물이 DL-메티오닌이거나 L-메티오닌인 안정화된 수용액.
  10. (a)안정화제는 L-메티오닌, DL-메티오닌, D-메티오닌, 및 그것의 혼합물중에서 선택하며, (b)약제학적 화합물은 미트아제핀, 마이안세린, 세티프틸린, 아이트립트린, 그것의 혼합물과 그것의 산부가염중에서 선택하며, (c)수용성 용매에 용해시켜서 안정화된 수용성 약제를 형성하는 것으로 구성된 안정화된 수용성 약제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900019904A 1989-12-06 1990-12-05 정신작용성 약물의 안정화된 용액 Expired - Fee Related KR0185377B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP892030925 1989-12-06
EP89203092 1989-12-06

Publications (2)

Publication Number Publication Date
KR910011250A true KR910011250A (ko) 1991-08-07
KR0185377B1 KR0185377B1 (ko) 1999-05-01

Family

ID=8202518

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900019904A Expired - Fee Related KR0185377B1 (ko) 1989-12-06 1990-12-05 정신작용성 약물의 안정화된 용액

Country Status (15)

Country Link
US (1) US5082864A (ko)
EP (1) EP0431663B1 (ko)
JP (1) JP2977912B2 (ko)
KR (1) KR0185377B1 (ko)
AT (1) ATE99943T1 (ko)
AU (1) AU628768B2 (ko)
CA (1) CA2030773C (ko)
DE (1) DE69005992T2 (ko)
DK (1) DK0431663T3 (ko)
ES (1) ES2062310T3 (ko)
FI (1) FI97689C (ko)
IE (1) IE63985B1 (ko)
NZ (1) NZ236332A (ko)
PT (1) PT96096B (ko)
ZA (1) ZA909568B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160080762A (ko) 2014-12-30 2016-07-08 김인호 전극보일러 급탕시스템
KR20170001494A (ko) 2015-06-26 2017-01-04 김인호 전극보일러 전류제어시스템

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH1591H (en) * 1992-10-09 1996-09-03 Fulcher; John Preparation of flavor-enhanced reduced calorie fried foods
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
CA2326356C (en) * 1998-04-02 2008-06-03 Akzo Nobel N.V. Oral liquid antidepressant solution
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
AU2002237847A1 (en) * 2001-02-12 2002-08-28 Akzo Nobel N.V Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
JP2007517901A (ja) * 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
WO2006023702A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
JP2008513455A (ja) * 2004-09-14 2008-05-01 モレキュラー セラピューティクス インコーポレーティッド 改良された生物薬剤学的性質をもつｄ−メチオニン製剤
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
WO2007067341A2 (en) * 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
CA2637359A1 (en) * 2006-01-17 2007-07-26 The Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for cns conditions
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
KR101971218B1 (ko) 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
JP6196041B2 (ja) * 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
RS60682B1 (sr) 2012-06-06 2020-09-30 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
PT3261645T (pt) 2015-02-27 2021-06-17 Dechra Ltd Estimulação do apetite, gestão da perda de peso, e tratamento da anorexia em cães e gatos
CN108853042B (zh) * 2018-09-20 2021-03-26 北京哈三联科技有限责任公司 一种米氮平冻干口崩片及其制备方法和应用
GR1009883B (el) * 2019-06-07 2020-12-11 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας Και Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη νορτριπτυλινη

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4603131A (en) * 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose
DE3247676A1 (de) * 1982-12-23 1984-06-28 A. Nattermann & Cie GmbH, 5000 Köln Galenische form fuer amitriptylinoxid und verfahren zur herstellung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160080762A (ko) 2014-12-30 2016-07-08 김인호 전극보일러 급탕시스템
KR20170001494A (ko) 2015-06-26 2017-01-04 김인호 전극보일러 전류제어시스템

Also Published As

Publication number Publication date
IE63985B1 (en) 1995-06-28
EP0431663B1 (en) 1994-01-12
DE69005992T2 (de) 1994-05-05
JP2977912B2 (ja) 1999-11-15
ES2062310T3 (es) 1994-12-16
IE904226A1 (en) 1991-06-19
DE69005992D1 (de) 1994-02-24
FI906008A0 (fi) 1990-12-05
PT96096B (pt) 1998-02-27
ATE99943T1 (de) 1994-01-15
CA2030773A1 (en) 1991-06-07
NZ236332A (en) 1992-07-28
PT96096A (pt) 1991-09-30
AU6779890A (en) 1991-06-13
DK0431663T3 (da) 1994-03-07
FI97689B (fi) 1996-10-31
ZA909568B (en) 1991-09-25
FI97689C (fi) 1997-02-10
KR0185377B1 (ko) 1999-05-01
FI906008L (fi) 1991-06-07
AU628768B2 (en) 1992-09-17
EP0431663A1 (en) 1991-06-12
CA2030773C (en) 2001-07-24
US5082864A (en) 1992-01-21
JPH05262651A (ja) 1993-10-12

Similar Documents

Publication Publication Date Title
KR910011250A (ko) 향정신성 약물의 안정화 용액
KR890001001B1 (ko) 안정화된 피록시캄 주사용액의 제조방법
RU2192249C2 (ru) Жидкая стабильная композиция на основе парацетамола и способ ее получения
ES2096091T7 (es) Nuevas composiciones a base de derivados de la clase de los taxanos.
NO148280B (no) Fremgangsmaate for fremstilling av tetracyklinpreparater
KR950007858A (ko) 정맥내 주사용 라파마이신 제형
KR870009998A (ko) 암로디핀의 베실레이트염의 제조방법
JPH07121861B2 (ja) ３−メチル−１−フエニル−２−ピラゾロン−５−オンを含有する安定な注射剤
KR850001300B1 (ko) 옥시테트라사이클린 조성물의 제조방법
KR950024769A (ko) 고농도 tcf 제제
US4128632A (en) Solubilization of Rafoxanide
KR880008801A (ko) 비경구 투여용 용액제
JP2001163776A (ja) 安定化された液剤
JPS6431727A (en) Dissolution of argininamide and drug composition containing argininamides
US4301175A (en) E-Type prostaglandin compositions
KR930023338A (ko) 데포우 제제
KR900014305A (ko) 소염제로서의 나프탈렌메탄아미노 유도체의 용도 및 이를 함유한 약학 조성물
PT97164A (pt) Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham
JPS62265220A (ja) １，４−ジヒドロキシ−５，８−ビス〔２−（２−ヒドロキシエチルアミノ）−エチルアミノ〕アントラキノン二塩酸塩の安定な注射用医薬配合物
IE50512B1 (en) Pharmaceutical injectable composition and two-pack container for said composition
JP7178512B2 (ja) 注入器用アドレナリン薬液
KR820000291B1 (ko) 불용성 약제의 가용화 방법
JP2002121416A (ja) 液状組成物
JPS6463552A (en) 4-biphenylylacetic acid ester-cyclodextrin inclusion compound
KR930006001A (ko) 티에노시클로펜탄온 옥심의 에테르, 그의 제법 및 그를 함유하는 제약학적 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19901205

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19951122

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19901205

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980622

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980925

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19981224

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19981224

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20011221

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20021217

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20031217

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20041216

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20051219

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20061219

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20071221

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20071221

Start annual number: 10

End annual number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20091110